Hematologic Malignancy
Diffuse Large B-Cell Lymphoma
CI-CAN-00005107DLBCLExplore in graph →
Hematologic355 active trials5 approved drugs19 evidence items
- NCIt
- C8851
- DOID
- 0050745
- Other
- 4 more codes
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005107DLBCLExplore in graph →
Clinical trials
1,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04875195 | A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68) | completed | Phase 2 | 66 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Oct 29, 2025 | clinicaltrials |
| NCT01760226 | Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies(DA-EPOCH-R) | completed | Early Phase 1 | 4 | Baylor College of MedicineOTHER | 1 | Oct 14, 2025 |
| clinicaltrials |
| NCT05526313 | Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant | completed | Phase 1 | 29 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07181785 | Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.(CHARTHER) | completed | — | 555 | Andrés José Maria FerreriOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT05267054 | Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab | completed | Phase 1 / Phase 2 | 53 | BeiGeneINDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04018248 | BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) | completed | Phase 1 | 26 | Boryung Pharmaceutical Co., LtdINDUSTRY | 2 | Sep 10, 2025 | clinicaltrials |
| NCT04772989 | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies(ARC-12) | completed | Phase 1 | 94 | Arcus Biosciences, Inc.INDUSTRY | 3 | Aug 28, 2025 | clinicaltrials |
| NCT07103486 | A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | completed | — | 264 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 5, 2025 | clinicaltrials |
| NCT02763319 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)(B-MIND) | completed | Phase 2 / Phase 3 | 453 | Incyte CorporationINDUSTRY | 23 | Jul 17, 2025 | clinicaltrials |
| NCT04833504 | Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma | completed | — | 39 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT02329080 | New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement | completed | Phase 2 | 79 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 4 | Jul 8, 2025 | clinicaltrials |
| NCT07041827 | Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma(CLARITY) | completed | — | 217 | The Netherlands Cancer InstituteOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT00001337 | Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 348 | National Cancer Institute (NCI)NIH | 1 | Jun 22, 2025 | clinicaltrials |
| NCT03742258 | Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma | completed | Phase 1 | 12 | Northwestern UniversityOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT05958134 | Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL | completed | — | 600 | AstraZenecaINDUSTRY | 1 | May 23, 2025 | clinicaltrials |
| NCT03583424 | Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 19 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT03939182 | Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma | completed | Phase 1 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT04566978 | 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL) | completed | Early Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT03311958 | Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance | completed | Early Phase 1 | 15 | Fox Chase Cancer CenterOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT05108805 | Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting | completed | Phase 4 | 25 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT03484819 | Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04537715 | Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels | completed | Phase 1 | 42 | Epizyme, Inc.INDUSTRY | 2 | Feb 19, 2025 | clinicaltrials |
| NCT03992339 | A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma(SEARCH) | completed | Phase 2 | 60 | Antengene CorporationINDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT04432506 | Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma | completed | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT03263026 | Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ | completed | Phase 3 | 256 | Denovo Biopharma LLCINDUSTRY | 2 | Jan 23, 2025 | clinicaltrials |
| NCT04890236 | Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study | completed | Early Phase 1 | 4 | Emory UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06782854 | Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy | completed | — | 102 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06777290 | Comparison of Whole-body MRI, Circulating DNA and PET-CT in Staging, Prognosis, and Treatment Response in Patients with Diffuse Large Cell B Lymphoma | completed | — | 14 | Charles University, Czech RepublicOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT02112526 | Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma | completed | Phase 1 | 21 | Acerta Pharma BVINDUSTRY | 2 | Dec 20, 2024 | clinicaltrials |
| NCT03129828 | Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2(ImbruVeRCHOP) | completed | Phase 1 / Phase 2 | 38 | Prof. Dr. Clemens SchmittOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT05233033 | Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL | completed | Phase 1 | 7 | Kymera Therapeutics, Inc.INDUSTRY | 2 | Dec 10, 2024 | clinicaltrials |
| NCT03145064 | Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma | completed | Phase 2 | 41 | BeiGeneINDUSTRY | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03520920 | BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) | completed | Phase 2 | 41 | BeiGeneINDUSTRY | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03955783 | Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies | completed | Phase 1 | 78 | Sanjay MohanOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03340766 | Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)(HARBOUR) | completed | Phase 1 | 31 | AmgenINDUSTRY | 6 | Oct 17, 2024 | clinicaltrials |
| NCT04134936 | Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL | completed | Phase 1 | 66 | MorphoSys AGINDUSTRY | 9 | Oct 16, 2024 | clinicaltrials |
| NCT02692248 | Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT | completed | Phase 2 | 64 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT01793233 | Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas | completed | — | 203 | Children's Oncology GroupNETWORK | 2 | Aug 26, 2024 | clinicaltrials |
| NCT04450069 | CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies | completed | Phase 1 | 18 | Calibr, a division of Scripps ResearchOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06549361 | A Retrospective Study on Extranodal DLBCL | completed | — | 5,023 | Ruijin HospitalOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT04555811 | FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL | completed | Phase 1 | 7 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT02631044 | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | completed | Phase 1 | 387 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 1 | Jun 27, 2024 | clinicaltrials |
| NCT04279405 | A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies | completed | Phase 1 | 43 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Jun 13, 2024 | clinicaltrials |
| NCT02564744 | Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL | completed | Phase 2 | 100 | Debiopharm International SAINDUSTRY | 9 | Jun 12, 2024 | clinicaltrials |
| NCT02199184 | Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT03424603 | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | completed | Phase 1 | 70 | Sutro Biopharma, Inc.INDUSTRY | 1 | Jun 11, 2024 | clinicaltrials |
| NCT02348216 | Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma(ZUMA-1) | completed | Phase 1 / Phase 2 | 307 | Kite, A Gilead CompanyINDUSTRY | 6 | Jun 4, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Oct 29, 2025source: clinicaltrials